Mode
Text Size
Log in / Sign up

Epigenetic mechanisms provide a molecular interface between genetic susceptibility and immune dysregulation in asthmaEpigenetic markers could help identify specific types of asthma

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that epigenetic signatures may eventually serve as biomarkers for asthma endotyping and therapeutic stratification.

This mini review explores the role of epigenetic mechanisms, such as DNA methylation, histone modifications, and noncoding RNAs, in the pathogenesis of asthma. The authors argue that these processes provide a critical molecular interface between an individual's genetic susceptibility, environmental exposures, and the resulting immune dysregulation.

Key findings suggest that epigenetic signatures have considerable potential as biomarkers for identifying inflammatory endotyping and informing therapeutic stratification. These mechanisms may help identify treatable traits and enhance the precision of medicine for patients with asthma.

However, the authors note that further validation is required before these markers can be used in routine clinical practice. The evidence is currently preliminary, and the potential of these biomarkers for clinical use is not yet established. The review highlights the theoretical importance of epigenetics in understanding the transition from exposure to disease, but clinical application remains a future goal.

How this fits prior evidence

This review addresses a gap in the understanding of the molecular drivers of asthma by focusing on the interface between environment and genetics. While previous coverage identified macrophage metabolic reprogramming as a driver of airway inflammation and noted that depemokimab shows no significant difference from other biologics, this review focuses on the underlying epigenetic mechanisms. It provides a different lens on how environmental factors, such as the extreme diurnal temperature range associated with increased asthma visits in children, might manifest as stable molecular changes.

Living with asthma can feel like a constant battle against an unpredictable environment. While many people have the condition, not everyone experiences the same symptoms or responds to the same medications. Researchers are looking into the molecular reasons why these differences exist, specifically focusing on how our bodies react to triggers.

Scientists are looking at epigenetics, which are chemical changes to our DNA that don't change the code itself but do change how our bodies read it. These changes act as a bridge between our genes and the environment. The study highlights how these markers can help identify specific types of inflammation and how well a person might respond to steroids.

While these markers have potential as tools to help doctors choose the right treatment for the right person, it is still early days. The research notes that more testing is needed before these methods can be used in everyday clinics. For now, it represents a promising path toward more personalized care for people with asthma.

What this means for you:
Epigenetic markers could eventually help doctors identify specific asthma types to provide more personalized treatment.

Common questions

What are epigenetic markers in asthma?

Epigenetic markers are chemical changes to your DNA, such as DNA methylation or histone modifications. These changes do not change your underlying genetic code, but they act as a bridge between your genes and your environment. They help explain how different people react differently to asthma triggers and how their immune systems behave.

How can these markers help with asthma treatment?

These markers have potential as biomarkers to help doctors identify specific types of inflammation. By identifying these specific traits, doctors may eventually be able to provide more precise medicine, choosing treatments that are better suited to a patient's specific type of asthma and their likely response to medications like corticosteroids.

Can these tests be used in clinics right now?

Not yet. While the research shows that these markers have potential for identifying treatable traits, the study notes that more validation is required before they can be used in routine clinical practice. You should continue to work with your doctor for your current asthma management.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Epigenetic mechanisms refer to heritable and potentially reversible modifications that regulate chromatin architecture and gene expression without altering the underlying DNA sequence. In asthma, these mechanisms provide a molecular interface between genetic susceptibility, environmental exposures, and immune dysregulation, contributing to disease heterogeneity and treatment response. The treatable traits paradigm, which focuses on the identification of specific modifiable biological and clinical characteristics, offers a clinically relevant framework for linking epigenetic changes to distinct molecular endotypes, enhancing mechanistic stratification beyond traditional phenotyping, thereby supporting precision medicine approaches. Emerging evidence suggests that epigenetic signatures have considerable potential as biomarkers for inflammatory endotyping and therapeutic stratification, although further validation is required before routine clinical implementation. In this mini review we will discuss epigenetic mechanisms involved in the development and maintenance of asthma processes, such as DNA methylation, histone modifications, and noncoding RNAs, focusing on their relevance to key treatable traits, including type 2 inflammation, corticosteroid responsiveness, airway remodeling, and exposure-driven disease.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.